Heparin-Coated Stent-Graft under the microscope: new analysis of nearly 1,000 patients

NCT ID NCT05459818

Completed Knowledge-focused Sponsor: Rijnstate Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study combines data from nearly 1,000 patients who received a special stent-graft (the GORE VIABAHN with a heparin coating) for peripheral artery disease in the leg. Researchers want to see how well the device keeps arteries open over time and which patient factors affect success. The goal is to better understand who benefits most from this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GORE® VIABAHN® endoprosthesis with heparin bioactive surface (a stent-graft device)
What this could lead to: If successful, this analysis could help doctors identify which patients with peripheral artery disease are most likely to benefit from this device, leading to better treatment decisions.
What could go wrong: This is a meta-analysis of existing studies, not a new trial. It cannot prove the device works better than other treatments, and results depend on the quality of the original studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral arterial disease peripheral vascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL VASCULAR DISEASES

Contacts and locations

Locations

Rijnstate

Arnhem, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.